How do you approach patients with SMARCB1 deficient sinonasal carcinoma for immunotherapy?
Answer from: Medical Oncologist at Academic Institution
Sinonasal cancers that are SMARCB1-deficient are rare. They tend to be more aggressive, present in more advanced stages, and tend to be associated with non-keratinizing histology. Despite this, there are no guidelines for a differential approach for these tumors and they are treated in a similar fas...